Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Evaluating the long-term effectiveness and safety of nivolumab and AVD chemotherapy combination in patients with early-stage unfavorable classical Hodgkin lymphoma.

Evaluating the long-term effectiveness and safety of nivolumab and AVD chemotherapy combination in patients with early-stage unfavorable classical Hodgkin lymphoma.

Posted by on Sep 17, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study reported the long-term safety and effectiveness of nivolumab (Opdivo; N) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations in patients with early-stage unfavorable classical Hodgkin lymphoma (cHL). The data showed that the N+AVD combination is safe and highly effective over the long term for these...

Read More

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.

Posted by on Aug 27, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of brentuximab vedotin (BV; Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the BV plus nivolumab combination...

Read More

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Posted by on Jun 11, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) before stem cell transplantation. The data showed that pembrolizumab was effective and safe with manageable side effects in these patients. Some background...

Read More

Evaluating the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma.

Evaluating the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma.

Posted by on Feb 28, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma (cHL). The data showed that patients with early-stage HL are at a higher risk of mortality from cardiovascular disease than from cancer. Some background cHL is a cancer that starts in white blood cells called...

Read More

Evaluating the effectiveness and safety of penpulimab in patients with relapsed or refractory classical Hodgkin lymphoma.

Evaluating the effectiveness and safety of penpulimab in patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Feb 5, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of penpulimab (AK105) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that penpulimab was effective and safe with manageable side effects in these patients. Some background Classical Hodgkin lymphoma (cHL) is a cancer of...

Read More

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Posted by on Sep 27, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

Posted by on Jun 1, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab-vedotin (Bv; Adcetris) combined with bendamustine (Treanda: B) as salvage treatment in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective in these patients....

Read More

Evaluating COVID-19 vaccination in immunocompromised patients with blood cancers

Evaluating COVID-19 vaccination in immunocompromised patients with blood cancers

Posted by on May 31, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell The study aimed to investigate if immunocompromised patients with blood cancers benefit from COVID-19 vaccination.  This study concluded that these patients should not be excluded from COVID-19 vaccination.  Some background Patients with blood cancers are at high risk for severe forms of COVID-19 disease due to lower...

Read More

Vacations for Adult Cancer Patients: Update

Vacations for Adult Cancer Patients: Update

Posted by on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update.  Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2025 Medivizor